Browse the latest research summaries in the field of pharmacology for spinal cord injury patients and caregivers.
Showing 111-120 of 639 results
Cells, 2023 • December 26, 2022
This study comprehensively investigates the roles of CCR1, CCR3, and their endogenous ligands in neuropathic pain using a murine model of chronic constriction injury (CCI). The research identifies tim...
KEY FINDING: CCL2/7/8 protein levels were significantly increased in the spinal cord following chronic constriction injury (CCI) of the sciatic nerve, suggesting their involvement in both the development and maintenance of neuropathic pain.
Int. J. Mol. Sci., 2023 • December 22, 2022
This review provides an overview of preclinical studies that highlight the positive effects of natural bioactive compounds in SCI and TBI experimental models through the activation of the Nrf2 pathway...
KEY FINDING: Several natural compounds can activate Nrf2 through multiple pathways, inducing a strong antioxidant response against CNS trauma.
Frontiers in Immunology, 2022 • December 22, 2022
The study investigates the role of the XCL1 chemokine and its receptors, XCR1 and ITGA9, in neuropathic pain using a chronic constriction injury (CCI) model in mice. Key findings include the upregulat...
KEY FINDING: XCL1 expression increases in the spinal cord after nerve injury and is mainly produced by astroglial cells.
Materials Today Bio, 2023 • January 7, 2023
This research focuses on developing a dual-targeting liposome (bFGF@Lip-Cp&Rp) to deliver basic fibroblast growth factor (bFGF) for spinal cord injury (SCI) treatment, addressing the challenges of dru...
KEY FINDING: The dual-targeted liposomes (bFGF@Lip-Cp&Rp) can effectively cross the BSCB and accumulate at the injury site in SCI rats.
Journal of Advanced Research, 2023 • January 27, 2023
This review systematically analyzes the role and mechanism of Nischarin/IRAS in the CNS, providing references and possible targets for neurological disease treatment and broadening the direction of Ni...
KEY FINDING: Nischarin/IRAS expression in the CNS is closely associated with the regulation of brain development, especially neuronal migration.
Pain, 2023 • July 1, 2023
The study identifies the VEGF-A/NRP1 interaction as a potential target for pain relief. Blocking this interaction with the compound NRP1-4 decreases sensory neuron excitability. NRP1-4 reduces pain-re...
KEY FINDING: NRP1–4 blocks the increase in excitability of sensory neurons caused by VEGF-A, suggesting it interferes with VEGF-A's action on these neurons.
Journal of Translational Medicine, 2023 • January 23, 2023
Our present study results suggest that elevated levels of sEH play an important role in neuropathic pain with anhedonia(Fig. 6). Moreover, TPPU may alleviate the anhedonia and pain behaviors in two w...
KEY FINDING: In anhedonia-susceptible mice, the tissue levels of sEH were significantly increased in the medial prefrontal cortex (mPFC), hippocampus, spinal cord, liver, kidney, and gut.
Evidence-Based Complementary and Alternative Medicine, 2023 • January 25, 2023
The study aimed to explore the molecular mechanism of Momordica grosvenori (MG) in spinal cord injury (SCI) by network pharmacology analysis. The current work indicated that MG might play an anti-SCI ...
KEY FINDING: The study identified 293 MG-anti-SCI targets by intersecting MG-related targets and SCI-related targets.
British Journal of Pharmacology, 2023 • May 1, 2023
This review assesses the existing evidence for Cav1.3-selective calcium channel blockers, which are of interest for treating various diseases. It finds that currently available compounds lack sufficie...
KEY FINDING: Current Cav1.3-selective blockers lack validation. The review finds no pharmacological tools suitable to confirm or refute a role of Cav1.3 channels in cellular responses due to selectivity issues.
Frontiers in Molecular Neuroscience, 2023 • January 30, 2023
This study investigated the therapeutic potential of Epimedium (EPI) for spinal cord injury (SCI) using network pharmacology and experimental validation. The research identified active ingredients and...
KEY FINDING: EPI improves behavioral performance in SCI rats, as indicated by improved Basso, Beattie, and Bresnahan scores.